他汀类药物与白内障关系的荟萃分析
发布时间：2018-10-13 16:17
【摘要】：目的:他汀类药物是否增加白内障的发生率一直以来都没有定论,各个研究之间得出的结论也都不一致,本研究旨在通过对现有已经发表的随机对照研究进行荟萃分析,客观评价使用他汀类药物后与白内障发生率的关系,为患者及临床医生更全面的了解他汀与白内障关系提供参考。方法:检索Pubmed,Embase,Cochrane协作网和Web of Science,按照纳入标准和排除标准对2017年1月前有关他汀类药物与白内障发生率的研究进行筛选,记录入选的研究他汀组及对照组(安慰剂组)新发白内障或行白内障手术的人数。使用RevMan5.3统计软件做荟萃分析。结果:共纳入6个随机对照研究,合计26534例患者,其中15417例患者接受他汀治疗,11117例患者接受安慰剂治疗,随访时间至少12个月。对纳入的6项研究进行荟萃分析,随访期间,他汀组与对照组相比,两组间白内障发生率未见显著性差异(RR:0.93,95%CI:0.75-1.14,P=0.46)。由于各个研究入选人群存在差异,剔除其中一项多中心,包含多个国家的人群的研究,进行亚组分析,发现他汀的使用可降低欧美人群白内障的风险(RR=0.83;95%CI:0.71-0.98,P=0.03)。对终点事件为临床白内障的5个研究进行分析,发现两组间白内障发生率无显著性差异(RR:0.94,95%CI:0.73-1.21,P=0.64)。结论:本研究结果表明,在总人群中,应用他汀类药物不会影响白内障的发生率。他汀对晶状体的作用在不同的人群中可能存在差异,在欧美人群中,他汀的使用可能降低白内障的发生率。只对终点事件为临床白内障的5项研究进行分析表明,他汀类药物不会增加患者临床白内障的发生率。
[Abstract]:Objective: whether statins increase the incidence of cataracts has been inconclusive and inconsistent across studies. The aim of this study was to conduct a meta-analysis of published randomized controlled studies. Objective evaluation of the relationship between statins and the incidence of cataract, for patients and clinicians a more comprehensive understanding of the relationship between statins and cataract. Methods: Pubmed,Embase,Cochrane collaboration and Web of Science, were searched for screening of statins and cataract incidence by January 2017 according to inclusion criteria and exclusion criteria. Record the number of new cataract or cataract operations in the statins group and control group (placebo group). Use RevMan5.3 statistical software to do meta-analysis. Results: a total of 26534 patients were enrolled in 6 randomized controlled trials, of which 15417 received statins and 11117 received placebo for at least 12 months. There was no significant difference in cataract incidence (RR:0.93,95%CI:0.75-1.14,P=0.46) between the statins group and the control group during the follow-up period. Because of the differences in the selected population, one of the multicenter studies including multiple countries was excluded and the subgroup analysis showed that the use of statins could reduce the risk of cataract (RR=0.83;95%CI:0.71-0.98,P=0.03) in the European and American population. There was no significant difference in the incidence of cataract between the two groups (RR:0.94,95%CI:0.73-1.21,P=0.64). Conclusion: the results of this study suggest that statins do not affect the incidence of cataract in the general population. The effects of statins on the lens may vary from population to population. In Europe and the United States, the use of statins may reduce the incidence of cataract. An analysis of only 5 studies in which the endpoint event was clinical cataract showed that statins did not increase the incidence of clinical cataract.
【学位授予单位】：浙江大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R776.1
，
本文编号：2269223
[Abstract]:Objective: whether statins increase the incidence of cataracts has been inconclusive and inconsistent across studies. The aim of this study was to conduct a meta-analysis of published randomized controlled studies. Objective evaluation of the relationship between statins and the incidence of cataract, for patients and clinicians a more comprehensive understanding of the relationship between statins and cataract. Methods: Pubmed,Embase,Cochrane collaboration and Web of Science, were searched for screening of statins and cataract incidence by January 2017 according to inclusion criteria and exclusion criteria. Record the number of new cataract or cataract operations in the statins group and control group (placebo group). Use RevMan5.3 statistical software to do meta-analysis. Results: a total of 26534 patients were enrolled in 6 randomized controlled trials, of which 15417 received statins and 11117 received placebo for at least 12 months. There was no significant difference in cataract incidence (RR:0.93,95%CI:0.75-1.14,P=0.46) between the statins group and the control group during the follow-up period. Because of the differences in the selected population, one of the multicenter studies including multiple countries was excluded and the subgroup analysis showed that the use of statins could reduce the risk of cataract (RR=0.83;95%CI:0.71-0.98,P=0.03) in the European and American population. There was no significant difference in the incidence of cataract between the two groups (RR:0.94,95%CI:0.73-1.21,P=0.64). Conclusion: the results of this study suggest that statins do not affect the incidence of cataract in the general population. The effects of statins on the lens may vary from population to population. In Europe and the United States, the use of statins may reduce the incidence of cataract. An analysis of only 5 studies in which the endpoint event was clinical cataract showed that statins did not increase the incidence of clinical cataract.
【学位授予单位】：浙江大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R776.1
，
本文编号：2269223
本文链接：https://www.wllwen.com/yixuelunwen/wuguanyixuelunwen/2269223.html
最近更新
教材专著
